Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Brain Neoplasms × Basiliximab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Hodgkin Disease 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Leukemia, Myeloid, Acute 3 Primary Myelofibrosis 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Glioblastoma 2 Anemia, Refractory, with Excess of Blasts 2 Neoplasms 1 Myelodysplastic Syndromes 1 Lymphoma, Mantle-Cell 1 Lymphoma, Extranodal NK-T-Cell 1 Hemoglobinuria, Paroxysmal 1 Hematologic Neoplasms 1 Gliosarcoma 1 Brain Neoplasms 1 Anemia, Aplastic 1

Interventions

Temozolomide 148 Radiosurgery 118 Radiotherapy 97 Bevacizumab 90 Magnetic Resonance Spectroscopy 70 Carboplatin 46 Etoposide 32 pembrolizumab 31 Surgical Procedures, Operative 31 Radiation 30 Irinotecan 30 Cyclophosphamide 30 Nivolumab 29 Erlotinib Hydrochloride 28 Carmustine 25 Lomustine 24 Trastuzumab 22 Ipilimumab 21 Filgrastim 21 Cisplatin 21 Aminolevulinic Acid 21 Mental Status and Dementia Tests 19 Magnetic Resonance Imaging 19 Vincristine 18 Surveys and Questionnaires 18 Capecitabine 18 Topotecan 17 Specimen Handling 17 Pemetrexed 16 Radiotherapy, Intensity-Modulated 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00626483 2021-03-09

REGULATe

Duke University

Phase 1 Completed

Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡